Table 3.
Gene expression analysis of DCK in a set of primary MCL samples obtained from patients before and after araC-based therapies
| Sample at diagnosis | Source | ∆CT (DCK-GAPDH) | Therapy | Sample at relapse | Disease-free survival (months) | Source | ∆CT (DCK-GAPDH) | Difference in ∆CT between R and D samples |
|---|---|---|---|---|---|---|---|---|
| D1 |
PBMC |
3.4 |
A* |
R1 |
12 |
PBMC |
3.7 |
+0.3 |
| D2 |
PE*** |
3.3 |
A |
R2 |
10 |
PE*** |
5.3 |
+2.0 |
| D3 |
FFPE |
0.1 |
A |
R3 |
5 |
FFPE |
1.3 |
+1.2 |
| D4 |
FFPE |
1.7 |
B |
R4 |
4 |
FFPE |
3.5 |
+1.8 |
| D5 |
PBMC |
1.4 |
A |
R5 |
7 |
PBMC |
2.2 |
+0.8 |
| D6 |
PBMC |
4.1 |
B** |
R6 |
3 |
PBMC |
3.9 |
−0.2 |
| D7 |
FFPE |
1.3 |
B |
R7 |
13 |
FFPE |
3.5 |
+2.2 |
| D8 |
FFPE |
2.0 |
A |
R8 |
25 |
FFPE |
1.8 |
−0.2 |
| D9 |
PBMC |
1.9 |
B |
R9 |
N/A |
PBMC |
3.3 |
+1.4 |
| D10 | PBMC | 2.3 | A | R10 | N/A | PBMC | 1.5 | −0.8 |
*A = alternation of R-CHOP and R-araC (2 g/m2, 2 doses a 24 h).
**B = Nordic protocol (alternation of R-MaxiCHOP and R-araC (2-3 g/m2, 4 doses a 12 h).
***PE pleural effusion (CD19-sorted).
Samples from relapsed patients were obtained at diagnosis (D1-D8) and at lymphoma relapse after failure of araC-based therapies (R1-R8). Samples from refractory patients were obtained from primary araC-resistant MCL patients before (D9-D10) and 14 days after (R9-R10) administration of high-dose araC. Real-time RT-PCR was used to determine changes in DCK expression.